Sun Pharma gets China NMPA approval for ILUMETRI to treat moderate-to-severe plaque psoriasis
In China clinical studies, the PASI 75 response rate reached a high level after 28 weeks of treatment with ILUMETRI and maintained…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Tildrakizumab
Sun Pharma launches ILUMYA (tildrakizumab) in Japan
It is indicated for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies…
Sun Pharma receives Japan MHLW approval of ILUMYATM for the treatment of Plaque Psoriasis
ILUMYA is one of the key specialty products of Sun Pharma and it was approved by US FDA in March 2018 while the European…
Sun Pharma Announces Regulatory Filing of Tildrakizumab in Japan
Japan is a key market with approximately 430,000 people currently suffering from psoriasis and psoriatic arthritis
Sun Pharma and CMS enter into a License Agreement for Cyclosporine A and Tildrakizumab in Greater…
Under the terms of the license agreement, CMS will pay Sun Pharma an initial upfront payment, regulatory and sales milestone…
Sun Pharma announces positive results of two phase-III CTs of Tildrakizumab
The IL-23p19 Therapeutic Antibody meets primary endpoints in both placebo-controlled studies and secondary endpoint in…